TuHURA Biosciences targets immunotherapy resistance, a key unmet need, with promising early data. Click here to find out why ...

As previously highlighted in our inaugural Akin Agency Transparency In Merger Enforcement (TIME) Report, merger enforcement ...

Coronation Fund Managers has engaged in responsible investing by voting on over 6,200 shareholder resolutions in 2024, ...

ACT staff members both past and present reflect on its legacy in Seattle theater as it hits a milestone birthday and merges ...

All eyes are on other legacy firms in New York, especially in the Second Hundred, as observers watch for merger pressures.

At its core, buy-and-build is a scaling play: PE firms acquire a well-positioned platform company and strategically bolt on ...